A history of suicide attempts (SA) appears to have lasting biological effects, reports a recent study, which shows that drops in circulating concentrations of the brain-derived neurotropic factor (BDNF) persist even beyond the current suicidal episode.
Blood clot removal in stroke patients presenting in later time window (6–24 hours) after symptom onset with a mismatch in clinical and imaging presentation ─ indicative of salvageable brain tissue that has not undergone infarction ─ can reduce disability from stroke and improve functional independence, according to the DAWN* trial.
Stress appears to disrupt the behavioural response of an infant to pain, suggests a new study, which shows that while stress amplifies the brain response to pain, infants may not react to the stimulus behaviourally, such as through facial expressions.
The oral pill fingolimod significantly reduces relapses vs interferon beta-1a in PARADIGMS, the first randomized controlled trial of fingolimod vs interferon beta-1a in paediatric multiple sclerosis (MS).
Some patients still do not feel comfortable with the magnetic resonance (MR) environment, and changing patient positioning (ie, feet-in first) does not necessarily help in minimizing claustrophobia, suggests a Singapore study.
Ozanimod ─ a novel selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator ─ led to greater reduction in relapse rate and brain atrophy in patients with relapsing multiple sclerosis (MS) in a head-to-head comparison with the first-line treatment interferon β-1a (IFN), according to the SUNBEAM and RADIANCE trials presented at the ECTRIMS-ACTRIMS Meeting 2017 held in Paris, France.
New drug applications approved by US FDA as of 1 - 15 November 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Ginkgo biloba has been shown to improve cognitive as well as neuropsychiatric symptoms (NPS) in patients with Alzheimer’s disease (AD) and mixed dementia. During a Schwabe-sponsored symposium last 20 October 2014 held at the University of Malaya in Malaysia, Professor Serge Gauthier of the McGill Centre for Studies in Aging in Quebec, Canada, and Dr Robert Hoerr of the Dr Willmar Schwabe GmbH & Co. KG in Germany, discussed studies that support the safety and efficacy of Ginkgo biloba extract (EGb 761®) in patients with AD and dementia.